TICKERNERD
Menu
PRCTPRCTHealthcare · Medical Devices

PRCT Stock Forecast: PROCEPT BioRobotics Corp. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$19
−4.09% on the day

The 14 Wall Street analysts covering PROCEPT BioRobotics Corp. hold a median 12-month price target of $21 — +13.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.1B
Ticker Nerd rank
38 / 100
Median analyst target
$21
Analysts covering
14
Revenue$94.5M+19.3% y/y
Operating income−$27.4M
Net income−$26.9M
Free cash flow−$22.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.9%
1M
−14.6%
YTD
−41.2%
1Y
−50.5%
From 52W high
−52.7%
From 52W low
+10.9%
$17
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PROCEPT BioRobotics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
71
Volatility
70
Accruals
60
Issuance
52
Value
47
Size
43
Revisions
43
Growth
37
Momentum
13

Quality (71): The business earns solid, repeatable profits on what it owns.

Momentum (13): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26PRCTHigh $28Median $21Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
4 Buy9 Hold1 Sell
Low $16Median $21High $28

The green dot is the last close — the median target sits +13.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Evercore ISI GroupMaintainsOutperform$30 → $23
5 Aug 2026Piper SandlerMaintainsOverweight$35 → $25
5 Aug 2026TD CowenMaintainsBuy$34 → $28
5 Aug 2026William BlairDowngradeMarket Perform—
28 July 2026UBSAssumesNeutral$20
6 July 2026Truist SecuritiesDowngradeHold—
6 July 2026Truist SecuritiesDowngradeHold$30 → $25
24 June 2026Evercore ISI GroupInitiatesOutperform—
11 June 2026Leerink PartnersDowngradeMarket Perform—
30 Apr 2026Piper SandlerReiteratesOverweight—
6 Mar 2026BairdInitiatesNeutral—
2 Mar 2026Truist SecuritiesMaintainsBuy—
26 Feb 2026B of A SecuritiesDowngradeUnderperform—
26 Feb 2026Leerink PartnersMaintainsOutperform—
26 Feb 2026OppenheimerDowngradePerform—
26 Feb 2026Piper SandlerMaintainsOverweight—
26 Feb 2026TD CowenMaintainsBuy—
26 Feb 2026Wells FargoMaintainsOverweight—
18 Dec 2025Truist SecuritiesMaintainsBuy—
12 Dec 2025UBSInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PRCT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, PROCEPT BioRobotics Corp. returned −50.5% against +15.7% for the S&P 500, dividends included.

PRCT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26PRCTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
10
Fundamentals

PROCEPT BioRobotics Corp. (PRCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.2×

Cheaper than 93% of US stocks

Price / sales
3.3×

Cheaper than 38% of US stocks

Price / book
3.2×

Cheaper than 30% of US stocks

EV / EBITDA
−8.7×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
19.3%

Higher than 68% of US stocks

Earnings growth (YoY)
19.3%

Higher than 58% of US stocks

Gross margin
66.0%

Higher than 79% of US stocks

Operating margin
−32.1%

Higher than 19% of US stocks

Net margin
−32.5%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−30.2%

Higher than 27% of US stocks

Return on assets
−14.8%

Higher than 23% of US stocks

Dividend yield
2.5%

Higher than 53% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PROCEPT BioRobotics Corp. (PRCT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PROCEPT BioRobotics Corp. has a market value of $1.1B and an enterprise value of $955.0M.

  • Revenue in the twelve months to 30 June 2026: $337.3M. The latest quarter grew 19.3% year on year.

  • Net income over the same four quarters: −$109.8M, a −32.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.94.

  • Free cash flow in the twelve months to 30 June 2026: −$84.9M.

  • Shares outstanding: 57.2M.

  • Trailing P/E: −11.2×; forward P/E: −16.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.49%, paying out 0% of earnings.

  • PROCEPT BioRobotics Corp. employs 888 people — $380K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

PRCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PRCTPROCEPT BioRobotics Corp.$1.1B
38
BVSBioventus, Inc.$1.1B
98
IRMDIRadimed Corp.$1.1B
89
LMRILumexa Imaging Holdings, Inc.$1.0B
1
AORTArtivion, Inc.$1.1B
41
ENOVEnovis Corp.$1.0B
80
BBNXBeta Bionics, Inc.$1.2B
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PROCEPT BioRobotics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRCT news & analysis

PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit

PRNewsWire · 21 Sept 2026negative

Rosen Law Firm, a global investor rights law firm, reminded purchasers of PROCEPT BioRobotics Corporation common stock during the Class Period of February 28, 2024 through February 25, 2026 of the September 22, 2026 lead plaintiff deadline in a securities fraud lawsuit.

Why it matters — PRCT watchers would care because the company faces a securities fraud lawsuit with an upcoming lead plaintiff deadline that investors who purchased during the Class Period may wish to consider.

Deadline Alert: PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

GlobeNewsWire · 21 Sept 2026negative

Glancy Prongay Wolke & Rotter LLP reminded PROCEPT BioRobotics investors of the September 22, 2026 deadline to file a lead plaintiff motion in a class action securities fraud lawsuit. The lawsuit covers investors who acquired PRCT securities between February 28, 2024 and February 25, 2026.

Why it matters — PRCT shareholders who purchased during the Class Period face an upcoming deadline related to an active securities fraud lawsuit against the company.

Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Seeking Recovery to Contact the Firm Before September 22, 2026

GlobeNewsWire · 21 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation on behalf of purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026. The firm is encouraging investors to contact it before September 22, 2026.

Why it matters — The company faces a class action lawsuit covering a two-year class period, which could carry legal and financial implications for PROCEPT.

PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law

GlobeNewsWire · 21 Sept 2026negative

SBS Law, a shareholder rights litigation firm, is reminding investors of a class action securities fraud lawsuit filed against PROCEPT BioRobotics Corporation, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

Why it matters — PRCT watchers would care because the company faces a securities fraud class action lawsuit alleging exchanges act violations that could carry legal and financial implications.

Long-Term Shareholders of PROCEPT BioRobotics Corporation (PRCT) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims

GlobeNewsWire · 21 Sept 2026negative

Johnson Fistel, PLLP announced it is investigating potential claims against certain officers and directors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for alleged breaches of fiduciary duty. The firm is encouraging current, long-term shareholders to contact it regarding these potential claims.

Why it matters — A law-firm investigation into alleged breaches of fiduciary duty by PRCT's officers and directors introduces legal and governance uncertainty for the company and its shareholders.

FAQ

Frequently asked questions about PRCT stock

What is the PRCT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering PROCEPT BioRobotics Corp. have a median 12-month price target of $21, with estimates ranging from $16 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRCT stock a buy right now?

Of the 14 analysts covering PROCEPT BioRobotics Corp., 4 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PROCEPT BioRobotics Corp. 38 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRCT?

As at 19 Sept 2026, PROCEPT BioRobotics Corp. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (71 of 100).

Will PRCT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +13.5% from the last close, and Ticker Nerd's factor model ranks PROCEPT BioRobotics Corp. 38 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRCT stock forecast for 2030?

No analyst covering PROCEPT BioRobotics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $28 over the next 12 months.

How has PRCT stock performed over the past year?

PROCEPT BioRobotics Corp. returned -50.5% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PROCEPT BioRobotics Corp. do?

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urology.

What is the latest news on PRCT?

The most recent item we track (PRNewsWire, 21 Sept 2026): "PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit". Rosen Law Firm, a global investor rights law firm, reminded purchasers of PROCEPT BioRobotics Corporation common stock during the Class Period of February 28, 2024 through February 25, 2026 of the September 22, 2026 lead plaintiff deadline in a securities fraud lawsuit.

Company

About PROCEPT BioRobotics Corp.

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urology. The company develops, manufactures, and sells the AquaBeam Robotic System and the HYDROS Robotic System, both designed for image-guided, minimally invasive urologic procedures. Its core offering is Aquablation therapy, a robotic treatment approach used primarily for benign prostatic hyperplasia and related lower urinary tract symptoms. PROCEPT BioRobotics also supports its systems with consumables, service, and clinical workflow tools that help hospitals and urology practices deliver precise, patient-specific care. The company serves healthcare providers in the United States and selected international markets, positioning itself within the medical device and surgical robotics segments of the healthcare industry.

CEO Mr. Larry L. Wood · 888 employees · United States · https://www.procept-biorobotics.com